Table 1.
Participant demographics and clinical information
| Participant features | T2DM | Nondiabetics |
|---|---|---|
| N | 77 | 735 |
| Age (<75:75–80:>80) (Mean ± SD) |
53 (68.83%):18 (23.38%):6 (7.80%) (70.48 ± 6.71) |
454 (61.77%):179 (24.35%):102 (13.88%) (72.17 ± 7.37) |
| Gender (M: F) | 46:31 | 384:351 |
| APOE ɛ4 carrier status (+/−) | 39:37 | 327:404 |
| APOE genotype (ɛ2/ɛ2: ɛ2/ɛ3: ɛ3/ɛ3: ɛ2/ɛ4: ɛ3/ɛ4: ɛ4/ɛ4) | 0 (0%):4 (5.19%):33 (42.86%):1 (1.30%): 32 (41.56%):6 (7.80%) | 1 (0.14%):59(8.03%):344 (46.80%):9 (1.22%): 245 (33.33%):73 (9.93%) |
| Education | 15.74 ± 2.44 | 16.31 ± 2.62 |
| HC: MCI: AD | 10:54:2 | 151:493:7 |
Abbreviations: AD, Alzheimer's disease; APOE, apolipoprotein epsilon; HC, healthy control; MCI, mild cognitive impairment; T2DM, type 2 diabetes mellitus; SD, standard deviation.